Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin
- 12 March 2014
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 170 (3), 609-616
- https://doi.org/10.1111/bjd.12658
Abstract
Psoriasis is a common immune-mediated inflammatory disease that affects the skin and joints. The interleukin (IL)-23/IL-17A axis and IL-22 play key roles in the pathogenesis of psoriasis. IL-23-responsive innate lymphoid cells (ILCs) with a high capacity to produce IL-17 and/or IL-22 have recently been identified and associated with inflammatory bowel diseases. The occurrence and role of ILCs in human skin are poorly understood. To describe the prevalence of the different ILC subpopulations in skin from healthy controls and patients with psoriasis or allergy to nickel. Skin biopsies were taken from healthy skin, nonlesional and lesional psoriatic skin, and nickel- and petrolatum-exposed skin from patients with contact allergy to nickel, and lymphocytes were isolated. The cells were stained and characterized by flow cytometry. Cytokine and ligand mRNA expression were measured by quantitative polymerase chain reaction. We found that members of the three groups of ILCs were present in human skin. Remarkably, the number and frequency of RORγt(+) CD56(+) ILC3s, which are known to produce IL-22, were elevated in both nonlesional and lesional skin from patients with psoriasis compared with healthy skin and skin from patients with contact allergy to nickel. Furthermore, skin ILCs expressed high levels of the natural killer receptor NKG2D. NKG2D binds to stress-induced ligands, including major histocompatibility complex class I-related chain A, which we found to be strongly upregulated in lesional skin from patients with psoriasis. These results show that ILCs are present in human skin and indicate that RORγt(+) CD56(+) ILC3 may be involved in the pathogenesis of psoriasis.Keywords
This publication has 39 references indexed in Scilit:
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque PsoriasisNew England Journal of Medicine, 2012
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for PsoriasisNew England Journal of Medicine, 2012
- PsoriasisAnnual Review Of Pathology-Mechanisms Of Disease, 2012
- Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin InflammationImmunity, 2011
- Cutting Edge: A Critical Functional Role for IL-23 in PsoriasisThe Journal of Immunology, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesThe Journal of Experimental Medicine, 2007
- IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasisEuropean Journal of Immunology, 2006
- In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic SkinThe Journal of Immunology, 2006
- Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis VulgarisThe Journal of Experimental Medicine, 2004